Patents by Inventor Thomas Malia

Thomas Malia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230287394
    Abstract: MHC multimers are provided in which peptide-loaded MHC monomers are covalently linked to a multimerization domain through conjugation moieties on the monomers and the multimerization domain. The multimers can further comprise oligonucleotide barcodes. Peptide exchange can be performed with a plurality of pMHC multimers to create pMHC multimer libraries. Methods of making and using the pMHC multimers and libraries are also provided. Peptide-loaded MHC Class I and MHC Class II multimers, and libraries thereof, are provided.
    Type: Application
    Filed: March 31, 2021
    Publication date: September 14, 2023
    Inventors: Ohad Yosefson, Thomas Malia, Andrew Hamel, Joanna Swain, Benjamin Roscoe, Mohammad Rashidian
  • Patent number: 11732050
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: August 22, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Publication number: 20230047413
    Abstract: Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and use of the antibodies for treating or preventing conditions such as tauopathies.
    Type: Application
    Filed: May 18, 2022
    Publication date: February 16, 2023
    Inventors: Marc Mercken, Thomas Malia, Marianne Borgers, Kristof Van Kolen
  • Patent number: 11365244
    Abstract: Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: June 21, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Marc Mercken, Thomas Malia, Marianne Borgers, Kristof Van Kolen
  • Publication number: 20210179696
    Abstract: Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.
    Type: Application
    Filed: August 6, 2020
    Publication date: June 17, 2021
    Inventors: Marc Mercken, Thomas Malia, Marianne Borgers, Kristof Van Kolen
  • Patent number: 10766953
    Abstract: Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: September 8, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Marc Mercken, Thomas Malia, Marianne Borgers, Kristof Van Kolen
  • Publication number: 20200277393
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Application
    Filed: May 19, 2020
    Publication date: September 3, 2020
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Patent number: 10689453
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: June 23, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Publication number: 20190248910
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Application
    Filed: April 12, 2019
    Publication date: August 15, 2019
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Patent number: 10301392
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: May 28, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Patent number: 10196440
    Abstract: The present invention relates to anti-PHF-tau antibodies and methods of making and using them.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: February 5, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Christopher Alderfer, Dariusz Janecki, Xuesong Liu, Melissa Murdock, Sheng-Jiun Wu, Marc Mercken, Marc Vandermeeren, Thomas Malia
  • Publication number: 20180305445
    Abstract: The present invention relates to anti-PHF-tau antibodies and methods of making and using them.
    Type: Application
    Filed: May 21, 2018
    Publication date: October 25, 2018
    Inventors: Christopher Alderfer, Dariusz Janecki, Xuesong Liu, Melissa Murdock, Sheng-Jiun Wu, Marc Mercken, Marc Vandermeeren, Thomas Malia
  • Publication number: 20180265575
    Abstract: Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.
    Type: Application
    Filed: March 16, 2018
    Publication date: September 20, 2018
    Inventors: Marc Mercken, Thomas Malia, Marianne Borgers, Kristof Van Kolen
  • Patent number: 10000559
    Abstract: The present invention relates to anti-PHF-tau antibodies and methods of making and using them.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: June 19, 2018
    Assignee: Janssen Biotech, Inc.
    Inventors: Christopher Alderfer, Dariusz Janecki, Xuesong Liu, Melissa Murdock, Sheng-Jiun Wu, Marc Mercken, Marc Vandermeeren, Thomas Malia
  • Publication number: 20170355758
    Abstract: The present invention relates to anti-PHF-tau antibodies and methods of making and using them.
    Type: Application
    Filed: July 11, 2017
    Publication date: December 14, 2017
    Inventors: Christopher Alderfer, Dariusz Janecki, Xuesong Liu, Melissa Murdock, Sheng-Jiun Wu, Marc Mercken, Marc Vandermeeren, Thomas Malia
  • Publication number: 20170320957
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Application
    Filed: May 16, 2017
    Publication date: November 9, 2017
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Patent number: 9745371
    Abstract: The present invention relates to anti-PHF-tau antibodies and methods of making and using them.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: August 29, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: Christopher Alderfer, Dariusz Janecki, Xuesong Liu, Melissa Murdock, Sheng-Jiun Wu, Marc Mercken, Marc Vandermeeren, Thomas Malia
  • Patent number: 9683046
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: June 20, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Publication number: 20160304593
    Abstract: The present invention relates to anti- PHF-tau antibodies and methods of making and using them.
    Type: Application
    Filed: April 26, 2016
    Publication date: October 20, 2016
    Inventors: Christopher Alderfer, Dariusz Janecki, Xuesong Liu, Melissa Murdock, Sheng-Jiun Wu, Marc Mercken, Marc Vandermeeren, Thomas Malia
  • Patent number: 9371376
    Abstract: Anti-PHF-tau antibodies and methods of making and using them are disclosed.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: June 21, 2016
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Christopher Alderfer, Dariusz Janecki, Xueson Liu, Melissa Murdock, Sheng-Jiun Wu, Marc Mercken, Marc Vandermeeren, Thomas Malia